Clinical trials: Hydroxychloroquine
Systemic Lupus Erythematosus
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms.
- Trial name
- SHIELD (NCT05799378)
- Testing
- Hydroxychloroquine
- Where
- 12 sites in United States
- Volunteers
- 330 people
- Sponsor
- NYU Langone Health
Melanoma Metastatic, NRAS Mutation
Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma.
- Trial name
- NCT07750067
- Testing
- Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
A standard treatment for patients with pancreatic cancer is standard photon radiation in combination with the chemotherapy drug, capecitabine.
- Trial name
- NCT01494155
- Testing
- Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Malaria,Falciparum, Anemia in Children
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent preventive treatment with dihydroartemisinin-piperaquine (IPT-DP).
- Trial name
- NCT06083688
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine-pyrimethamine-amodiaquine
- Where
- Malawi
- Volunteers
- 788 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Corona Virus Infection
Trial of Treatments for COVID-19 in Hospitalized Adults
DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the…
- Trial name
- DisCoVeRy (NCT04315948)
- Testing
- Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A
- Where
- 62 sites in Austria, Belgium and 5 more
- Volunteers
- 1,552 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Lupus Nephritis
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children
The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
- Trial name
- NCT07675291
- Testing
- rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide
- Volunteers
- 112 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer Stage IIB
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
- Trial name
- NCT03032406
- Testing
- Hydroxychloroquine, Everolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Colorectal Cancer
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).
- Trial name
- NCT05843188
- Testing
- Hydroxychloroquine, Irinotecan, Leucovorin
- Where
- 2 sites in Canada
- Volunteers
- 155 people
- Sponsor
- University Health Network, Toronto
Rheumatoid Arthritis
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.
- Trial name
- NCT03414502
- Testing
- Methotrexate, Abatacept, Adalimumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Nebraska
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
This is a Phase II, open label, single-arm trial study of adding hydroxychloroquine to encorafenib and cetuximab in patients with metastatic BRAF V600E colon cancer with progression on at least 1 prior line of therapy.
- Conditions
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
- Trial name
- NCT05576896
- Testing
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Psoriasis, Atopic Dermatitis
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
- Trial name
- NCT07352566
- Testing
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Breast Cancer
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio).
- Trial name
- ABBY (NCT04523857)
- Testing
- Abemaciclib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Ductal Adenocarcinoma
PHL Treatment in Pancreatic Cancer
This proposal will investigate the effect of paricalcitol, hydroxychloroquine, and losartan (PHL) combination of 3 stroma-modifying drugs on pancreatic adenocarcinoma and its stroma.
- Trial name
- NCT05365893
- Testing
- Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
COVID-19, End Stage Renal Disease
The Danish Pre-HCQ COVID Dialysis Study
Hydroxychloroquine has been shown to inhibit replication of SARS-CoV-2 in vitro. The presented multicenter parallel-group open-label randomized clinical trial aims to investigate the efficacy of prophylactic hydroxychloroquine on…
- Trial name
- NCT05110651
- Testing
- Hydroxychloroquine
- Where
- 3 sites in Denmark
- Sponsor
- Nicholas Carlson
Recurrent Osteosarcoma, Refractory Osteosarcoma
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
This phase I/II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not…
- Trial name
- NCT03598595
- Testing
- Docetaxel, Gemcitabine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the…
- Conditions
- Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Trial name
- THREAD (NCT03825289)
- Testing
- Hydroxychloroquine, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Prostate Cancer Recurrent, Solid Tumor, Adult
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers.
- Trial name
- COAST (NCT05036226)
- Testing
- Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Medical University of South Carolina
Pancreatic Ductal Adenocarcinoma
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based…
- Trial name
- NCT05630989
- Testing
- combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy with MEKi-EGFRi
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mandana Kamgar, MD